Abbott has secured FDA approval for its Navitor TAVI device to treat aortic stenosis. Credit: Abbott.

The US Food and Drug Administration (FDA) has approved Abbott’s latest-generation transcatheter aortic valve implantation (TAVI) system, named Navitor, for the treatment of aortic stenosis.

Navitor has been designed to treat severe aortic stenosis in people who are at high or extreme risk for open-heart surgery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It comprises a special fabric cuff (NaviSeal) to reduce or eliminate paravalvular leak (PVL), which is the backflow of blood around the valve frame.

Abbott claims that Navitor is the only self-expanding TAVI system with leaflets in the native valve.

This design helps improve access to coronary arteries, enabling future procedures for the treatment of coronary artery disease.

The company’s FlexNav delivery system is used to implant the Navitor device, which provides hemodynamics, or blood flow, through the valve.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FlexNav delivery system has a slim design, which allows it to accommodate various patient anatomies, and small vessels for stable, predictable and accurate delivery and placement of the valve.

Abbott Structural Heart Business senior vice-president Michael Dale said: “Our Navitor valve builds upon our industry-leading portfolio of minimally invasive devices that surpass existing standards of care to address a range of heart diseases.

“Navitor is the first TAVI system to offer optimal hemodynamics in all valve sizes while also preserving options for lifetime disease management, an important consideration for physicians and patients when selecting a TAVI solution.

“Receiving this approval is a major next step in our mission to help people live better lives through better health.”

The company stated that the Navitor device is the newest addition to its extensive transcatheter structural heart portfolio, which provides physicians and patients with less invasive treatment alternatives for common, serious heart diseases.